White House trade adviser Peter Navarro is leading a Trump administration effort to demand the Food and Drug Administration reverse course and grant a second emergency authorization for the antimalarial drug hydroxychloroquine to treat covid-19, the disease caused by the
coronavirus.
Navarro, armed with a new study that he says shows the drug’s effectiveness, is being cheered on by President Trump, who has long touted the drug as a “game changer” and
even used it himself as a possible preventive measure. Trump praised the study
on Twitter this week, urging the FDA to “Act Now.” The campaign also has been promoted by Rudolph W. Giuliani, the president’s lawyer, and Laura Ingraham’s show on Fox News.
But Navarro, an economist known more for his aggressive approach to
trade issues and China policy than for his medical credentials, faces serious challenges as he denounces what he calls “media-induced hydroxy hysteria.” Scientists have widely criticized the new study, by Detroit’s Henry Ford Health System, as flawed. In addition, just weeks ago the FDA
revoked its emergency authorization for hydroxychloroquine after major studies found the medication wasn’t effective for covid-19. And the unexpected revival of a politically fraught issue comes as FDA Commissioner Stephen M. Hahn tries to shake off criticism he sometimes seems overly deferential to Trump.
“A reversal [on hydroxychloroquine] would be widely seen as bending to the political will of the White House, and the hit to Dr. Hahn’s credibility would be profound,” said Steven Joffe, a medical ethicist at the University of Pennsylvania.
The FDA’s response to this pressure will be closely watched, not only because the White House has already been criticized for pushing to influence the Centers for Disease Control and Prevention’s guidelines for the pandemic but also because the agency will take the lead in
approving a vaccine for the coronavirus, a decision that could potentially affect millions. Health experts say it is important for the agency, which was criticized for its initial decision to okay hydroxychloroquine in March, to guard its credibility as it prepares to make these landmark
decisions for a public sometimes skeptical of vaccines.
The tug-of-war on hydroxychloroquine also is seen by many as a test for Hahn. ...